Clinical Trial Update: Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for pulsed oral sirolimus in autosomal dominant polycystic kidney disease is reported, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Medical University of Vienna | Conditions: Polycystic Kidney, Type 1 Autosomal Dominant Disease, Polycystic Kidney, Type 2 Autosomal Dominant Disease | Phase 3 | Status: UNKNOWN